DEF: Cingulate Seeks Shareholder Nod for $25M Capital Raise

Cingulate Inc. is calling a special stockholder meeting to approve the issuance of over 20% of its common stock to Lincoln Park Capital Fund, LLC, enabling access to up to $25 million in capital.

Summary

• A Special Meeting of Stockholders will be held on September 25, 2025, at 10:00 a.m. Central Time, in a virtual format.
• The primary purpose is to approve the issuance of more than 20% of common stock to Lincoln Park Capital Fund, LLC (LPC) to comply with Nasdaq Listing Rule 5635(d).
• This approval would allow the company to sell up to $25.0 million worth of common stock to LPC over a 36-month period.
• The company has already issued 120,424 commitment shares to LPC as consideration for its commitment.
• Without stockholder approval, the company is limited to issuing 1,004,660 shares (including commitment shares) at a price less than $5.6537 per share under Nasdaq rules.
• The second proposal seeks approval to adjourn the Special Meeting to a later date if insufficient votes are received for the Issuance Proposal.
• As of the record date, August 1, 2025, 5,264,642 shares of common stock were outstanding and entitled to vote.

Sentiment

Score: 6

Explanation: The filing presents a necessary step for securing capital, which is positive for funding operations and development. However, the significant potential for dilution and the need for shareholder approval for the full amount introduce uncertainty and a clear negative impact on existing shareholders' equity and voting power. The overall sentiment is neutral to slightly positive, as access to capital is crucial for a development-stage company, but the terms involve substantial dilution.

Positives

• Secures a potential source of capital of up to $25.0 million through the purchase agreement with Lincoln Park Capital Fund, LLC.
• Provides flexibility to access capital when and as needed over a 36-month period, which is crucial for funding ongoing operations and development.
• Funds are intended for critical activities including regulatory approval, development, manufacturing, and commercialization of CTx-1301, as well as general corporate purposes and research and development efforts.

Negatives

• The sale of shares to Lincoln Park will have a dilutive effect on existing stockholders, impacting their voting power and economic rights.
• If stockholder approval is not obtained, the company will be unable to issue shares in excess of the Nasdaq 20% Rule Exchange Cap (1,004,660 shares) if sold at a price less than the Minimum Price ($5.6537 per share), limiting the potential capital raise.
• The issuance of additional shares, if approved, may result in a decline in the stock price or greater price volatility due to increased supply.

Risks

• Failure to obtain stockholder approval for the Issuance Proposal would limit the company's ability to raise the full $25.0 million from Lincoln Park Capital Fund, LLC under the current terms.
• The issuance of additional common stock will dilute the ownership and voting power of current stockholders.
• Increased share count due to dilution may lead to a decline in stock price or increased price volatility.
• The company's ability to sell shares to Lincoln Park is subject to certain limitations, including a minimum stock price of $0.50 for regular purchases and Lincoln Park not beneficially owning more than 4.99% (or 9.99% with notice) of common stock.

Future Outlook

The company intends to use the net proceeds from the potential sale of securities to Lincoln Park Capital Fund, LLC for obtaining regulatory approval, development, manufacturing, and commercialization activities of CTx-1301, as well as for working capital, capital expenditures, and general corporate purposes, including further research and development efforts. The agreement provides a flexible source of capital over a 36-month period, contingent on stockholder approval for the full amount.

Management Comments

• The Board unanimously recommends that you vote FOR the Issuance Proposal.
• The Board unanimously recommends that you vote FOR the Adjournment Proposal.
• Our Board has determined that the Purchase Agreement with Lincoln Park is in the best interests of the Company and its stockholders because the right to sell shares to Lincoln Park provides the Company with a potential source of capital and the ability to access that capital when and as needed.

Industry Context

This filing reflects a common strategy for smaller, publicly traded companies, particularly in the biopharmaceutical sector (implied by CTx-1301 and R&D focus), to secure flexible funding through equity lines of credit or at-the-market (ATM) facilities. Such agreements provide access to capital without the immediate dilution or fixed costs of traditional debt or underwritten offerings, allowing companies to fund ongoing development and commercialization efforts, which are capital-intensive in the pharmaceutical industry.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential significant dilution of voting power and economic rights due to the issuance of a large number of new shares.
• Company Operations/Development: Access to up to $25.0 million in capital will fund critical activities such as regulatory approval, development, manufacturing, and commercialization of CTx-1301, potentially accelerating product timelines.
• Creditors: A stronger cash position from the capital raise could improve the company's financial stability, potentially benefiting creditors.

Next Steps

• Hold Special Meeting of Stockholders on September 25, 2025, to vote on the Issuance Proposal and Adjournment Proposal.
• If the Issuance Proposal is approved, the company can proceed with selling shares to Lincoln Park Capital Fund, LLC in excess of the Nasdaq 20% Rule Exchange Cap.
• If the Issuance Proposal is not approved, the company will be limited in its ability to raise the full $25.0 million from Lincoln Park Capital Fund, LLC.
• Publish final voting results in a Current Report on Form 8-K within four business days of the Special Meeting.
• Continue development, manufacturing, and commercialization activities for CTx-1301 using proceeds from the capital raise.

Key Dates

Recommendation

The filing indicates a crucial step for Cingulate Inc. to secure necessary funding for its CTx-1301 development and general operations. Access to $25 million is a positive for a company in the biopharmaceutical development stage, as it provides financial runway. However, this capital comes at the cost of significant potential dilution to existing shareholders, which could negatively impact per-share value and stock price. The 'hold' recommendation reflects the balance between the positive of securing capital for future growth and the negative of immediate and potential future dilution. Investors should monitor the outcome of the shareholder vote and the subsequent utilization of funds, as well as the progress of CTx-1301, before making further investment decisions.

Keywords

Cingulate Inc., SEC Filing, DEF 14A, Proxy Statement, Capital Raise, Stock Issuance, Nasdaq Listing Rule 5635(d), Lincoln Park Capital Fund, Dilution, CTx-1301, Biopharmaceutical, Special Meeting, Shareholder Vote